AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9313279 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer ratings for cream alone
Number of subjects: 117
Study 8384050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive applied to the raw surface of liver resections for 20 patients
Number of subjects: 40
Study 8384050 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing applied) for 20 patients
Number of subjects: 40
Study 3512971 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin + 4'epi‐adriamycin + cyclophosphamide (PEC)
Number of subjects: 51
Study 3512971 — intervention group
Group type: COMPARATOR
Intervention: cisplatin + adriamycin + cyclophosphamide (PAC)
Number of subjects: 51
Study 30081275 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 2800
Study 30081275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study 27168572 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth coaching promoting nutrition and exercise
Number of subjects: 234
Study 27168572 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study 25023055 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive lamivudine
Number of subjects: 258
Study 25023055 — intervention group
Group type: COMPARATOR
Intervention: No antiviral prophylaxis
Number of subjects: 258
Study 25023055 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBV reactivation
Number of subjects: 258
Study 22613532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine (0.1 - 0.2 µg × kg(‐1)× min(‐1) intravenous infusion from PCI to 24 hours after PCI)
Number of subjects: 177
Study 22613532 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline (control group)
Number of subjects: 177
Study 20220748 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 186
Study 20220748 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 24 mg
Number of subjects: 186
Study 20220748 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 186
Study 20220748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 18224311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg oral dose) with clarithromycin (800 mg/day)
Number of subjects: 18
Study 18224311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg oral dose) with fluvoxamine (50 mg/day)
Number of subjects: 18
Study 18224311 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (60 mg oral dose) with placebo
Number of subjects: 18
Study 12100205 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g daily
Number of subjects: 2
Study 12100205 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1 g daily (follow-up)
Number of subjects: 2
Study 12100205 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticosteroids (highly dosed)
Number of subjects: 2
Study 9589224 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.7 mmol MgO daily for 30 days
Number of subjects: 128
Study 9589224 — intervention group
Group type: EXPERIMENTAL
Intervention: 41.4 mmol MgO daily for 30 days
Number of subjects: 128
Study 9589224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 8025966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization using ethiodized oil (Lipiodol) and anticancer agents (Mitomycin in 40 patients, DADH in 58 patients)
Number of subjects: 114
Study 8025966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial embolization (TAE) with Gelfoam or Ivalon sponge
Number of subjects: 114
Study 8025966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization plus TAE (repeated in 56 patients)
Number of subjects: 114
Study 2607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 70
Study 2607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol plus INH
Number of subjects: 70
Study 2607570 — intervention group
Group type: EXPERIMENTAL
Intervention: INH plus rifampicin
Number of subjects: 70
Study 2607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 70
Study 2607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 70
Study 31914556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 120
Study 31914556 — intervention group
Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 120
Study 31362966 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) - robot‐assisted or laparoscopic radical hysterectomy (RH)
Number of subjects: 1448
Study 31362966 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (RH)
Number of subjects: 1448
Study 27861700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 4,000 IU daily for 9 months
Number of subjects: 130
Study 27861700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 26437506 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain-fused-to-metal-like crowns (PFM)
Number of subjects: 56
Study 26437506 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically-guided crowns (AG)
Number of subjects: 56
Study 26437506 — intervention group
Group type: COMPARATOR
Intervention: Flat design crowns (FD)
Number of subjects: 56
Study 23571719 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week energy-restricted diet intervention
Number of subjects: 78
Study 21757112 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (Sim‐T)
Number of subjects: 14
Study 21757112 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (Conv‐T)
Number of subjects: 14
Study 19858396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² with cisplatin 50 mg/m² (arm A)
Number of subjects: 245
Study 19858396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,500 mg/m² at a fixed dose rate of 10 mg/m²/min (arm B)
Number of subjects: 245
Study 19858396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² with docetaxel 40 mg/m² (arm C)
Number of subjects: 245
Study 19858396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² with irinotecan 100 mg/m² (arm D)
Number of subjects: 245
Study 16997053 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CML level
Number of subjects: 450
Study 16997053 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 450
Study 16997053 — intervention group
Group type: EXPERIMENTAL
Intervention: History of prior cardiovascular events
Number of subjects: 450
Study 16997053 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary albumin-creatinine ratio
Number of subjects: 450
Study 14970134 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil by bolus injection
Number of subjects: 64
Study 14970134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11642083 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoton therapy
Number of subjects: 106
Study 11642083 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy (TLT) without neoton
Number of subjects: 106
Study 11642083 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy (TLT) with streptokinase preparations
Number of subjects: 106
Study 11642083 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (TLT) with streptokinase preparations and neoton
Number of subjects: 106
Study 9407640 — intervention group
Group type: EXPERIMENTAL
Intervention: New mononuclear cell collection program
Number of subjects: 7
Study 9407640 — intervention group
Group type: COMPARATOR
Intervention: PBSC‐LYM program
Number of subjects: 7
Study 8220968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol per kilogram body weight (kgbw)
Number of subjects: 28
Study 8220968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol per kilogram body weight (kgbw)
Number of subjects: 28
Study 3324137 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 3324137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31539436 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Handshake Method (LHM)
Number of subjects: 32
Study 31539436 — intervention group
Group type: COMPARATOR
Intervention: Traditional Method (TM)
Number of subjects: 32
Study 28112467 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3230
Study 28112467 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Number of subjects: 3230
Study 24602091 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Caloric Restriction (CR: 3.2 kcal/kg body weight per day, 8-h walking + 45-min arm cranking per day)
Number of subjects: 15
Study 24602091 — intervention group
Group type: COMPARATOR
Intervention: Control diet + reduced exercise
Number of subjects: 15
Study 24602091 — intervention group
Group type: EXPERIMENTAL
Intervention: Post WCR (4 weeks)
Number of subjects: 15
Study 24602091 — intervention group
Group type: EXPERIMENTAL
Intervention: Post WCR (1 year)
Number of subjects: 15
Study 24602091 — intervention group
Group type: EXPERIMENTAL
Intervention: WCR
Number of subjects: 15
Study 24602091 — intervention group
Group type: COMPARATOR
Intervention: DIET
Number of subjects: 15
Study 24602091 — intervention group
Group type: EXPERIMENTAL
Intervention: POST1
Number of subjects: 15
Study 22798152 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT)
Number of subjects: 10
Study 21531706 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment after first seizure
Number of subjects: 419
Study 21531706 — intervention group
Group type: COMPARATOR
Intervention: Treatment only in the event of seizure recurrence
Number of subjects: 419
Study 21531706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treated and untreated)
Number of subjects: 419
Study 19333174 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 64
Study 19333174 — intervention group
Group type: COMPARATOR
Intervention: Self-care book
Number of subjects: 64
Study 16413347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet, exercise, and stress management
Number of subjects: 93
Study 16413347 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 93
Study 15243303 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 48
Study 15243303 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 48
Study 11510794 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 720
Study 11510794 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 720
Study 8988885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine 1
Number of subjects: 46
Study 8988885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine 2
Number of subjects: 46
Study 8988885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine 3
Number of subjects: 46
Study 8988885 — intervention group
Group type: COMPARATOR
Intervention: Control (unimmunized)
Number of subjects: 46
Study 8233271 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mg naproxen suppositories
Number of subjects: 60
Study 8233271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3660461 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 136
Study 3660461 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination
Number of subjects: 136
Study 30731451 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3342
Number of subjects: 90
Study 30731451 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 90
Study 30731451 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + AZD3342
Number of subjects: 90
Study 27126905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based education (telephone-delivered educational session and phone/text access to a nurse for 30 days after delivery)
Number of subjects: 178
Study 27126905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based education
Number of subjects: 178
Study 27126905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile phone-based education)
Number of subjects: 178
Study 24796227 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (12-week, 6-session, phone-based)
Number of subjects: 59
Study 24796227 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 59
Study 24796227 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention
Number of subjects: 59
Study 22875143 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring service for COPD patients
Number of subjects: 38
Study 21034476 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDT) with individualized fluid replacement
Number of subjects: 70
Study 21034476 — intervention group
Group type: EXPERIMENTAL
Intervention: ScvO2 ≥ 71%
Number of subjects: 70
Study 21034476 — intervention group
Group type: EXPERIMENTAL
Intervention: P(cv-a)CO2
Number of subjects: 70
Study 21034476 — intervention group
Group type: EXPERIMENTAL
Intervention: ScvO2 ≥ 71% with P(cv-a)CO2
Number of subjects: 70
Study 21034476 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 70
Study 18763691 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg HPP-containing tablets
Number of subjects: 28
Study 18763691 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg HPP-containing tablets
Number of subjects: 28
Study 18763691 — intervention group
Group type: COMPARATOR
Intervention: 0% HPP control tablets
Number of subjects: 28
Study 17000362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 34
Study 17000362 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging
Number of subjects: 34
Study 14602747 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogen (114 mg isoflavonoids)
Number of subjects: 56
Study 14602747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10951436 — intervention group
Group type: EXPERIMENTAL
Intervention: deflazacort (0.9 mg/kg/day)
Number of subjects: 18
Study 10951436 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone (0.75 mg/kg/day)
Number of subjects: 18
Study 10951436 — intervention group
Group type: COMPARATOR
Intervention: untreated DMD patients (natural history control)
Number of subjects: 18
Study 8797398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms per puff, max 16 puffs)
Number of subjects: 257
Study 8797398 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (100 micrograms per puff, max 16 puffs)
Number of subjects: 257
Study 8797398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms per puff)
Number of subjects: 257
Study 8797398 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (100 micrograms per puff)
Number of subjects: 257
Study 8797398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 257
Study 1474082 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg iv)
Number of subjects: 9
Study 6706302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein (80 gm per day)
Number of subjects: 37
Study 6706302 — intervention group
Group type: COMPARATOR
Intervention: Branched-chain enriched amino acid solution (BCAA, 80 gm per day)
Number of subjects: 37
Study 6706302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein
Number of subjects: 37
Study 6706302 — intervention group
Group type: COMPARATOR
Intervention: Branched-chain enriched amino acid solution (BCAA)
Number of subjects: 37
Study 31814710 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib as maintenance therapy following chemotherapy
Number of subjects: 28
Study 31814710 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib as palliative following chemotherapy
Number of subjects: 28
Study 31814710 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib alone as salvage therapy
Number of subjects: 28
Study 31814710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of Apatinib
Number of subjects: 28
Study 29691947 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 0
Study 29691947 — intervention group
Group type: COMPARATOR
Intervention: Adolescent focused therapy
Number of subjects: 0
Study 27252412 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg GTL001 + imiquimod
Number of subjects: 47
Study 27252412 — intervention group
Group type: COMPARATOR
Intervention: 600 μg GTL001 + placebo cream
Number of subjects: 47
Study 27252412 — intervention group
Group type: COMPARATOR
Intervention: placebo + imiquimod
Number of subjects: 47
Study 25285696 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Number of subjects: 79
Study 25285696 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 79
Study 22445475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockroft & Gault (C&G)
Number of subjects: 19
Study 22445475 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
Number of subjects: 19
Study 22445475 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h creatinine clearance
Number of subjects: 19
Study 22445475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of Diet in Renal Disease (MDRD-6)
Number of subjects: 19
Study 22445475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C-based estimation
Number of subjects: 19
Study 22445475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of Diet in Renal Disease (MDRD-4)
Number of subjects: 19
Study 18790588 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house semi-nested PCR assay targeting the 16S rRNA gene of Eubacteria
Number of subjects: 112
Study 17680515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential SV‐CABG (seqSV‐CABG)
Number of subjects: 90
Study 17680515 — intervention group
Group type: COMPARATOR
Intervention: Single SV‐CABG (sSV‐CABG)
Number of subjects: 90
Study 17169645 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic infiltration of 6 mL 1% lidocaine
Number of subjects: 120
Study 17169645 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic and apical infiltration: 4 mL 1% lidocaine at the prostate-seminal vesicle junction and 2 mL infiltration at the prostatic apex
Number of subjects: 120
Study 12578924 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Treatment (VT) using the Lee Silverman Voice Treatment method
Number of subjects: 0
Study 12578924 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Treatment (VT)
Number of subjects: 0
Study 12578924 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no treatment)
Number of subjects: 0
Study 12578924 — intervention group
Group type: COMPARATOR
Intervention: VT-untreated patients
Number of subjects: 0
Study 10578771 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling program
Number of subjects: 291
Study 10578771 — intervention group
Group type: COMPARATOR
Intervention: No peer counseling
Number of subjects: 291
Study 8711707 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with autologous stem cell support
Number of subjects: 90
Study 8711707 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 90
Study 1898434 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 7
Study 1898434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6362729 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 61
Study 6362729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 61
Study 6362729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 31776726 — intervention group
Group type: EXPERIMENTAL
Intervention: R-GEM-L (lenalidomide + rituximab + methylprednisolone + gemcitabine)
Number of subjects: 34
Study 31776726 — intervention group
Group type: COMPARATOR
Intervention: R-GEM-P (rituximab + methylprednisolone + gemcitabine)
Number of subjects: 34
Study 31531572 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with bilateral superficial cervical plexus blockade (G2)
Number of subjects: 100
Study 31531572 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (G1)
Number of subjects: 100
Study 29040873 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention group (Drive Smart training)
Number of subjects: 25
Study 29040873 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention group (documentary video followed by Drive Smart training)
Number of subjects: 25
Study 27030499 — intervention group
Group type: EXPERIMENTAL
Intervention: medicated genefix IUD
Number of subjects: 840
Study 27030499 — intervention group
Group type: EXPERIMENTAL
Intervention: medicated γ IUD
Number of subjects: 840
Study 27030499 — intervention group
Group type: COMPARATOR
Intervention: control group (no IUD or steroids)
Number of subjects: 840
Study 25289942 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (18 μg)
Number of subjects: 126
Study 25289942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 21959560 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about AV fistula care
Number of subjects: 32
Study 18789646 — intervention group
Group type: EXPERIMENTAL
Intervention: High support during birth
Number of subjects: 137
Study 18789646 — intervention group
Group type: COMPARATOR
Intervention: Low support during birth
Number of subjects: 137
Study 18789646 — intervention group
Group type: EXPERIMENTAL
Intervention: High stressful events
Number of subjects: 137
Study 18789646 — intervention group
Group type: COMPARATOR
Intervention: Low stressful events
Number of subjects: 137